March 23, 2023

The Spring 2023 advocacy blog Considering Clinical Trials is now available

February 23, 2023

A focus on the DREAMseq trial reveals data-driven clinical insights into the selection of first-line treatment options for patients with BRAF-mutated metastatic melanoma

October 4, 2022

DREAMseq trial clarifies immunotherapy, targeted treatment order for patients with BRAF-mutant metastatic melanoma

September 30, 2022

Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy

September 28, 2022

Immunotherapy before targeted therapy improves survival in advanced melanoma, according to the DREAMseq trial

September 27, 2022

Media Advisory: Journal of Clinical Oncology publishes outcomes from the practice-changing DREAMseq trial in patients with advanced melanoma

September 26, 2022

The Fall 2022 advocacy blog Considering Clinical Trials is now available

June 6, 2022

Dr. Michael Atkins discusses the DREAMseq trial in patients with advanced melanoma

May 27, 2022

Press Release: ECOG-ACRIN research highlights at ASCO 2022

ECOG-ACRIN Cancer Research Group